Related Experiment Video
Updated: Jun 21, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
TLR7 in systemic lupus erythematosus: genetics and emerging therapies
Carola G Vinuesa1, Madhumita Shrotri2,3, Anisur Rahman3
1The Francis Crick Institute, London, UK. carola.vinuesa@crick.ac.uk.
Abstract:
Systemic lupus erythematosus (SLE) is a disease with considerable unmet treatment needs. Endosomal nucleic acid sensing by Toll-like receptor 7 (TLR7) is emerging as a key pathogenic pathway. Gain-of-function mutations in the genes encoding TLR7 and its chaperone UNC93B1 can cause monogenic childhood-onset SLE; rare variants in proteins that regulate ligand availability or downstream signalling proteins also contribute to disease. TLR7 variants can increase the affinity of this receptor for its ligands and can alter binding to endogenous antagonists. Both self RNA-protein complexes and viruses have been implicated in TLR7 activation. Key pathogenic mechanisms include breakdown in B cell tolerance and autoantibody production and type I interferon secretion. Although current therapies such as B cell-depleting chimeric antigen receptor (CAR) T cells and anifrolumab (anti-type I interferon receptor) offer benefit, they are limited by high costs and lack of oral options. In this context, TLR7 has emerged as a promising therapeutic target. Phase II trials of an oral dual TLR7-TLR8 antagonist show durable suppression of the interferon signature in all patients, indicating that TLR7 and TLR8 drive this signature in SLE. This treatment has shown clinical benefit for SLE and cutaneous lupus erythematosus, although the primary endpoint (a dose-response effect) was only met in cutaneous lupus erythematosus. Thus, TLR7-TLR8 antagonists might reshape SLE treatment, alone or in combination with other drugs.
Insights
Toll-like receptor 7 (TLR7) plays a key role in systemic lupus erythematosus (SLE) pathogenesis. Targeting TLR7 and TLR8 with oral antagonists shows promise for treating SLE, offering a potential new therapeutic avenue.
Area of Science:
- Immunology
- Rheumatology
- Genetics
Background:
- Systemic lupus erythematosus (SLE) presents significant unmet treatment needs.
- Endosomal nucleic acid sensing via Toll-like receptor 7 (TLR7) is a critical pathogenic pathway in SLE.
- Genetic variations in TLR7 and related proteins contribute to SLE development and progression.
Purpose of the Study:
- To investigate the therapeutic potential of targeting Toll-like receptor 7 (TLR7) in systemic lupus erythematosus (SLE).
- To evaluate the efficacy of oral dual TLR7-TLR8 antagonists in managing SLE and related conditions.
Main Methods:
- Review of current understanding of TLR7's role in SLE pathogenesis.
- Analysis of Phase II clinical trial data for oral dual TLR7-TLR8 antagonists.
- Assessment of treatment effects on interferon signatures and clinical outcomes in SLE and cutaneous lupus erythematosus.
Main Results:
- TLR7 variants can enhance receptor affinity for ligands and alter interactions with antagonists.
- Oral dual TLR7-TLR8 antagonists demonstrated durable suppression of the interferon signature in all SLE patients.
- Clinical benefits were observed in SLE and cutaneous lupus erythematosus, with a significant dose-response effect noted in cutaneous lupus erythematosus.
Conclusions:
- TLR7 is a validated therapeutic target for systemic lupus erythematosus.
- Oral TLR7-TLR8 antagonists represent a promising therapeutic strategy for SLE, potentially offering an oral treatment option.
- These antagonists may significantly alter the treatment landscape for SLE, possibly in combination therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Pharmacogenomics: Identification of New Drug Targets